Anaplasma platys Detection Using Species-Specific Polypeptides

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic tests for distinguishing Anaplasma platys (Apl) and Anaplasma phagocytophilum (Aph) infections have limited specificity, and serological tests using Aph polypeptides or antibodies often fail to detect all instances of Apl infection or exposure.

Innovation Solution

Development of purified polypeptides and antibodies specific to Apl, including the p44 polypeptide, for use in detecting antibodies and nucleic acids in biological samples, employing methods such as PCR and immunosorbent assays to accurately identify Apl and Aph infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current diagnostic tests are used to distinguish Apl and Aph infections, then the testing process is simple, but the specificity and accuracy of detection is limited

Engineering Contradiction:

Improvedetection specificityVSAvoidtest complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the detection approach by using species-specific polypeptides (such as Apl p44, p35, and p27) as distinct antigens for differentiating between Apl and Aph infections. This segmentation allows the diagnostic test to specifically target and detect antibodies against particular Anaplasma species, thereby improving detection specificity while maintaining a manageable test structure through defined polypeptide targets.

Inventive Principle:

Principle #1Segmentation

2Measurement precision

If serological tests using Aph polypeptides or antibodies are used, then the test structure is established, but the detection sensitivity for Apl infection is insufficient

Engineering Contradiction:

Improvedetection sensitivityVSAvoidtest development difficulty

Core Design Contradiction:

Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent extracts species-specific polypeptides (Apl p44, p35, p27) from the broader Anaplasma genus to create targeted diagnostic antigens. By isolating and using these specific polypeptides rather than general Anaplasma antigens, the test achieves higher sensitivity for detecting Apl-specific antibodies, while the extraction and characterization of these polypeptides provides a clear pathway for test development.

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If purified polypeptides specific to Apl are developed for detection, then the detection accuracy is improved, but the manufacturing and assay development becomes more complex

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidpolypeptide production complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies local quality by focusing on specific, well-defined polypeptide regions (such as the p44 polypeptide with specific amino acid sequences) that exhibit high species-specificity. This localized approach to antigen selection allows for concentrated efforts on producing and characterizing key polypeptides, improving diagnostic reliability while managing manufacturing complexity through targeted production of essential antigens rather than entire protein complexes.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solution provides robust and specific detection of Apl and Aph infections, allowing for accurate diagnosis and differentiation between the two, even in early stages of exposure or infection.

Implementation Method 1

contacting a purified polypeptide of the invention with a test sample, under conditions that allow polypeptide/antibody complexes to form

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

The polypeptide/antibody complexes can be contacted with an indicator reagent that generates a measurable signal prior to the performance of the detection step

Methodology Applied

Scientific EffectSignal generation: